This study is focused on participants who have diabetic kidney disease. The aim of this study is to see how safe and effective the study drugs are.
Please note that this clinical trial will use an investigational drug product that has not yet been approved for use outside of clinical trials. The safety and efficacy of the investigational drug product have not been fully evaluated by Regulatory Authorities and has not received marketing authorization in any country.
This study is testing an investigational drug called GIGA-2339. We want to see if it is safe and easy to handle. We also want to see how your immune system reacts to it, how your body processes it, and what effect it has on your health.
This study is being done to learn more about maridebart cafraglutide (MariTide [formerly AMG 133]) in people with heart failure (HF) and obesity in addition to their routine medical care.
We are doing this study to learn more about a new drug called AZD7760 when it is given as an intravenous (IV; into the vein) infusion to healthy adults (Phase I) or adults with end‑stage kidney disease who are on hemodialysis with a central venous catheter (Phase IIa).
We are doing this study to learn more about how effective, safe and tolerable an experimental drug called balcinrenone is when used in combination with dapagliflozin for treating patients with heart failure and impaired kidney function and also to better understand the studied disease and associated health problems.
We are doing this study to learn more about an experimental drug called AZD1613, and also to better understand ADPKD and associated health problems.
